GETNE Registration of Thyroid Cancer
ConditionThyroid Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGrupo Espanol de Tumores Neuroendocrinos
About this trial
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
Patients who agree to participate and are able to understand the information sheet and sign the informed consent
Disqualifiers
Patients under 18 years of age.
Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
Trial population
Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.
Trial design
Design model
Ecologic or community
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Hystopathological characteristics of the tumor
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Time frame
Baseline2
Situation of the tumor at first-diagnosis
Local tumor, locoregional tumor or metastatic disease.
Time frame
Baseline3
Tumor-Node-Metastasis classification
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time frame
Baseline4
Tumor Stage
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Time frame
BaselineSecondary outcomes
1
Patient situation at the end of treatment
Results of clinical evaluation of the disease including complete response, partial response, stable disease, progression of disease or death
Time frame
12 months2
Number of patients with BRAF mutation
Total patients with available results on BRAF status and proportion of patients with mutated BRAF or native BRAF.
Time frame
12 months3
Number of patients with RET mutation
Total patients with available results on RET status and proportion of patients with mutated RET or native RET.
Time frame
12 months4
Number of patients with PI3K mutation
Total patients with available results on PI3K status and proportion of patients with mutated PI3K or native PI3K.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov